Axsome Therapeutics Inc (NASDAQ:AXSM)

70.77
Delayed Data
As of Oct 22
 +1.82 / +2.64%
Today’s Change
20.48
Today|||52-Week Range
109.94
-31.53%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$2.7B

Company Description

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Contact Information

Axsome Therapeutics, Inc.
22 Cortlandt Street
New York New York 10007
P:(212) 332-3241
Investor Relations:

Employees

Shareholders

Other institutional39.82%
Mutual fund holders23.98%
Individual stakeholders23.93%

Top Executives

Herriott TabuteauChairman, President & Chief Executive Officer
Mark L. JacobsonChief Operating Officer & Secretary
Nick PizzieChief Financial Officer
Amanda JonesVice President-Clinical Research
Cedric O'GormanSenior VP-Clinical Development & Medical Affairs